Tag: Dysglycemia

A study in *The New England Journal of Medicine* found patients taking gatifloxacin had a 17-fold increased likelihood of hyperglycemia. This article explains **why is gatifloxacin banned** and details the severe risks that led to its market withdrawal for systemic use.

While once used for a variety of systemic bacterial infections, oral tablets containing the antibiotic gatifloxacin—marketed under brand names like Getz Tablet—were withdrawn from many markets, including North America, due to serious adverse effects. The primary concern was the medication's tendency to cause abnormally high or low blood sugar levels, leading to a ban on its systemic use. Today, gatifloxacin is primarily available in ophthalmic (eye drop) form for treating bacterial eye infections, as the systemic toxicity was not observed with topical application.

Studies show that repeated exposure to certain antibiotic classes, such as quinolones, is associated with an increased risk of developing new-onset diabetes [1.2.4]. Understanding **what antibiotics are linked to diabetes** is crucial for both patients and healthcare providers to manage blood glucose effectively.